Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214876 | 0.97 | ALDH1A1 (0.48) | ALDH1A1THRBKMT2AMEN1GAA | |
| SCHEMBL16214841 | 0.93 | ALDH1A1 (0.51) | ALDH1A1THRBKMT2AMEN1GAA | |
| SCHEMBL16214834 | 0.88 | ALDH1A1 (0.43) | ALDH1A1THRBKMT2AMEN1GAA | |
| SCHEMBL16214016 | 0.86 | ALDH1A1 (0.51) | ALDH1A1THRBKMT2AMEN1GAA | |
| SCHEMBL16214875 | 0.85 | ALDH1A1 (0.42) | ALDH1A1THRBKMT2AMEN1GAA | |
| SCHEMBL16214034 | 0.83 | ALDH1A1 (0.50) | ALDH1A1THRBKMT2AMEN1GAA | |
| SCHEMBL16214818 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAALMNANPSR1L3MBTL1 | |
| SCHEMBL16214829 | 0.81 | ALDH1A1 (0.45) | ALDH1A1THRBKMT2AMEN1GAA | |
| SCHEMBL12556624 | 0.80 | ALDH1A1 (0.46) | ALDH1A1THRBKMT2AMEN1GAA | |
| SCHEMBL16214015 | 0.79 | ALDH1A1 (0.53) | ALDH1A1THRBKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877960-B2 | Fluoroalkanesulfonic acid ammonium salts and method for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20110313190-A1 | Fluoroalkanesulfonic Acid Ammonium Salts and Method for Producing Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313190-A1 | Fluoroalkanesulfonic Acid Ammonium Salts and Method for Producing Same | PFAS, ARSA, NOTUM | ALDH1A1 1460/4885THRB 4382/4885KMT2A 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.